Caplyta (lumateperone) is not classified as an antidepressant. It is an atypical antipsychotic, but the line between drug classes gets blurry with this medication because it is FDA-approved specifically to treat depressive episodes associated with bipolar I and bipolar II disorder. It also has strong clinical trial data supporting its use alongside antidepressants for major depressive disorder (MDD), though that indication has not yet received full FDA approval.
What Caplyta Is Approved to Treat
Caplyta currently has two FDA-approved uses: schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder. For bipolar depression, it can be prescribed on its own or alongside lithium or valproate. It is one of only two medications (along with quetiapine) that carry FDA approval for bipolar II depression specifically, a condition that has historically had very few approved treatment options.
The fact that Caplyta targets depressive episodes is a big part of why people wonder whether it’s an antidepressant. Traditional antipsychotics were developed primarily for psychosis and mania. Caplyta works differently at the brain chemistry level, affecting serotonin, dopamine, and glutamate signaling in a way that appears to lift depression without the heavy sedation or metabolic side effects common with older antipsychotics.
How It Performed in Bipolar Depression Trials
The FDA approved Caplyta for bipolar depression based on two pivotal clinical trials, both lasting about six weeks. In one study testing Caplyta as a standalone treatment, patients saw their depression scores drop by 16.7 points on a standard rating scale, compared to 12.1 points for those taking a placebo. That 4.6-point difference is considered clinically meaningful in psychiatry research.
A second study tested Caplyta as an add-on to lithium or valproate. The improvement over placebo was smaller (2.4 points) but still statistically significant. In both trials, the dose was the same: one 42 mg capsule taken once daily, with no need to gradually increase the dose over time. That simplicity is notable because many psychiatric medications require weeks of careful dose adjustments before reaching therapeutic levels.
Caplyta for Major Depressive Disorder
While Caplyta isn’t approved for MDD yet, phase 3 clinical trials have produced strong results. In a randomized, double-blind trial, patients who had not responded adequately to their existing antidepressant were given Caplyta as an add-on. After six weeks, the Caplyta group improved by nearly 5 points more than those who added a placebo to their antidepressant, with an effect size of 0.61, which researchers consider moderate to large. A second, similarly designed study also showed clinically meaningful benefits.
This matters because treatment-resistant depression is common. Roughly one-third of people with MDD don’t get adequate relief from their first antidepressant, and options for what to add next are limited. If Caplyta eventually gains FDA approval for MDD, it would give doctors another tool for patients stuck in that frustrating cycle of trying medication after medication.
Why the Drug Class Distinction Matters
Calling Caplyta an antipsychotic rather than an antidepressant isn’t just a technicality. The classification affects how the drug is prescribed, what side effects are monitored, and what regulatory warnings it carries. All antipsychotics, including Caplyta, come with a boxed warning about increased mortality risk in older adults with dementia-related psychosis. They also carry monitoring requirements for metabolic changes like blood sugar and cholesterol that traditional antidepressants don’t.
That said, Caplyta’s side effect profile is generally lighter than many other antipsychotics. It causes less weight gain, less sedation, and fewer movement-related side effects than medications like quetiapine or olanzapine, which are also sometimes used for bipolar depression. For someone whose primary problem is depression rather than psychosis, this distinction can make the medication easier to tolerate day to day.
What This Means Practically
If you’ve been prescribed Caplyta for depression, you’re not being treated for psychosis. Your doctor is using a medication that happens to belong to the antipsychotic class but has clear, well-studied antidepressant effects. The standard dose is 42 mg once daily, taken with or without food, and you don’t need to ramp up slowly. Most people start at the full therapeutic dose on day one.
If you have bipolar disorder, Caplyta is an FDA-backed option for depressive episodes. If you have MDD and haven’t responded well to antidepressants alone, your doctor may prescribe it off-label based on the clinical trial evidence, though formal approval for that use may still be on the way. Either way, the medication’s mechanism of action genuinely targets depression, even if its official classification says “antipsychotic” on the label.